Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites

• Published in: European journal of gynaecological oncology Vol. 38; no. 2; pp. 209 - 213
• Main Authors: Liu, E L, Mi, R R, Wang, D H, Wang, L Q, Zhang, Y M, Chen, W M
• Format: Journal Article
• Language: English
• Published: Italy 2017
• Subjects: Administration, Intravenous; Aged; Alzheimer Disease - complications; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Ascites - etiology; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin - administration & dosage; Cytoreduction Surgical Procedures; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial - complications; Neoplasms, Glandular and Epithelial - secondary; Neoplasms, Glandular and Epithelial - therapy; Operative Time; Ovarian Neoplasms - complications; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Survival Rate; Taxoids - administration & dosage
• ISSN: 0392-2936
• DOI: 10.12892/ejgo3446.2017

The aim of this study was to explore the effects of neoadjuvant chemotherapy in senile patients with advanced ovarian can- cer and ascites. One hundred eight senile patients with advanced ovarian cancer and ascites were randomly di- vided into two groups: experimental and control groups. Patients in the experimental group were treated with two courses of intraperitoneal combined with intravenous neoadjuvant chemotherapy, followed by cytoreductive surgery, and six courses of intravenous chemotherapy, while the patients in the control group only received cytoreductive surgery and six to eight courses of intravenous chemotherapy. The operation duration, blood loss, ideal success rate of cytoreductive surgery, and prognosis of the two groups were then compared. Thirty-eight patients in the experimental group successfully received cytoreductive surgery, accounting for 74.14%, while only 23 patients in the control group received cytoreductive surgery successfully, accounting for 46%, showing signifinificantly less than those in the control group (p < 0.001). However, the median survival and the median progression-free survival showed no statistical difference between the two groups (p > 0.05). Neoadjuvant chemotherapy can obviously shorten the operation duration, reduce the intraoperative blood loss, and improve the ideal success rate of cytoreductive surgery, but does not obviously improve the prognosis.